^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

Published date:
09/21/2021
Excerpt:
...the effectiveness of afatinib in patients with stage IIIB/IV lung adenocarcinoma...Afatinib demonstrated clinical activity across a set type of specific rare uncommon mutations, including EGFR L747P, A767_V769dup, and L833V/H835L...Our findings suggested that afatinib is effective in patients with uncommon mutations.
DOI:
10.1158/2159-8290.CD-21-0715
Evidence Level:
Sensitive: D – Preclinical
Title:

Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma

Published date:
06/03/2021
Excerpt:
Eighty-four organoids were established from patients with advanced lung adenocarcinoma….YUO-004 and YUO-050 harboring an EGFR L747P mutation was sensitive to afatinib…
DOI:
10.1158/1078-0432.CCR-20-5026